Spyre Therapeutics (SYRE) Enterprise Value (2015 - 2026)
Spyre Therapeutics (SYRE) posted Enterprise Value of -$739.7 million for Q1 2026, up 2.22% on a QoQ basis from -$756.5 million in Q4 2025, and down 30.97% year-over-year from -$1.1 billion in Q1 2025.
Spyre Therapeutics (SYRE) Enterprise Value (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Enterprise Value history runs 12 years deep, the most recent figure standing at -$739.7 million for Q1 2026.
- Quarterly Enterprise Value fell 30.97% year-over-year to -$739.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$739.7 million (down 30.97% YoY) and the FY2025 annual result came in at -$756.5 million, down 25.8% from the prior year.
- Enterprise Value was -$739.7 million for Q1 2026 at Spyre Therapeutics, up from -$756.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$38.5 million in Q1 2023 and bottomed at -$756.5 million in Q4 2025.
- A 5-year average of -$358.8 million and a median of -$414.2 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value soared 47.32% — and 2024, when it tumbled 1159.53%.
- Spyre Therapeutics' Enterprise Value stood at -$55.7 million in 2022, then plunged by 508.99% to -$339.3 million in 2023, then tumbled by 77.26% to -$601.4 million in 2024, then slipped by 25.8% to -$756.5 million in 2025, then advanced by 2.22% to -$739.7 million in 2026.
- Business Quant data shows SYRE's Enterprise Value at -$739.7 million in Q1 2026, -$756.5 million in Q4 2025, and -$486.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | -739.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -739.73 Mn |
| Dec 31, 2025 | -756.53 Mn |
| Sep 30, 2025 | -486.20 Mn |
| Jun 30, 2025 | -524.88 Mn |
| Mar 31, 2025 | -564.82 Mn |
| Dec 31, 2024 | -601.40 Mn |
| Sep 30, 2024 | -414.23 Mn |
| Jun 30, 2024 | -426.00 Mn |
| Mar 31, 2024 | -484.64 Mn |
| Dec 31, 2023 | -339.28 Mn |
| Sep 30, 2023 | -203.60 Mn |
| Jun 30, 2023 | -235.36 Mn |
| Mar 31, 2023 | -38.48 Mn |
| Dec 31, 2022 | -55.71 Mn |
| Sep 30, 2022 | -73.68 Mn |
| Jun 30, 2022 | -88.55 Mn |
| Mar 31, 2022 | -66.73 Mn |
| Dec 31, 2021 | -93.13 Mn |
| Sep 30, 2021 | -112.43 Mn |
| Jun 30, 2021 | -128.58 Mn |